Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Revlimid
Pharma
BMS accentuates the positive after Cobenfy trial flop
On the heels of a clinical setback for BMS' schizophrenia newcomer Cobenfy, the company has served up mixed results for 2025's first quarter.
Fraiser Kansteiner
Apr 24, 2025 11:31am
After $1.5B cost-cutting plan, BMS will cut an additional $2B
Feb 6, 2025 8:33am
CEO says BMS can handle impact of IRA price negotiation
Jul 26, 2024 11:36am
ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma
Dec 12, 2023 12:00pm
Sanofi targets first-line myeloma as Sarclisa delivers trial win
Dec 7, 2023 11:26am
BMS aims for staggering 25 label expansions in the coming years
Sep 15, 2023 12:04pm
